landmarknew treatment
Midostaurin FDA-approved for advanced systemic mastocytosis
Systemic Mastocytosis →Summary
In April 2017, midostaurin became the first FDA-approved targeted therapy for advanced SM (ASM, SM-AHN, and MCL) based on a phase II open-label trial showing overall response rate of 60% including 45% major responses. This represented the first targeted option beyond cytoreductive chemotherapy for advanced SM subtypes.
More from Systemic Mastocytosis
significantTreatment update
PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM
significantNew research
Swedish and Danish population-based studies reveal higher SM prevalence than expected
breakthroughTreatment update
Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)
incrementalTreatment update
Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable
ID: systemic-mastocytosis-update-5Type: new_treatmentImpact: landmark